HRT Financial’s Zevra Therapeutics ZVRA Stock Holding History

HRT Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,389	Closed	-$66K	–	3310
2022 Q4	$66K	Buy	+14,389	New	+$73.1K	﹤0.01%	2100
2019 Q4	–	Sell	-694	Closed	-$7K	–	1737
2019 Q3	$7K	Buy	+694	New	+$12.5K	﹤0.01%	1359

Other funds holding ZVRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

HRT Financial's ZVRA Position: Q1 2023 in Review

HRT Financial sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 14,389 shares — an estimated $66K sold.

HRT Financial first reported a position in ZVRA in Q3 2019 and held it in 2 quarters. The position peaked at $66K in Q4 2022. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

HRT Financial reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
HRT Financial sold 14,389 Zevra Therapeutics shares in Q1 2023, an estimated $66K.
HRT Financial first reported a position in Zevra Therapeutics in Q3 2019 and held it in 2 quarters.
HRT Financial's Zevra Therapeutics position peaked at $66K in Q4 2022.
60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.